Hims & Hers (NYSE:HIMS) fell ~8% in the premarket Thursday after a federal judge denied a motion filed by a compounding trade group over the FDA’s decision to declare that Eli Lilly’s (NYSE:LLY) ...
Zacks Investment Research on MSN
Hims & Hers Expands Care Scope as Prescription Platforms Evolve
The renowned health and wellness platform, Hims & Hers Health, Inc.’s HIMS, business model links virtual consultations ...
What To Know: While Hims & Hers doesn’t manufacture the GLP-1 drugs, a class of medications that help manage Type 2 diabetes and obesity, like Eli Lilly’s Zepbound and Novo Nordisk’s Ozempic, it sells ...
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, is redefining healthcare delivery through a vertically integrated, technology-driven model that merges telemedicine, data ...
Shares of Hims & Hers are trending Thursday morning. The San Francisco-based telehealth company announced an international ...
Hims & Hers stock jumped 6% in post-market trading Monday after the company said it was in active discussions to make Wegovy injections and Novo Nordisk’s forthcoming obesity pill available through ...
Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, ...
NEW YORK, Dec 10 (Reuters) - Online telehealth company Hims and Hers Health is launching its weight-loss membership and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback